Single Cycle of Blinatumomab Followed By High-Dose Chemotherapy in the Induction Therapy for Ph-Negative Acute Lymphoblastic Leukemia in Adults. Primary Endpoint Analysis of the Blina-Cell Trial
SALEK, Cyril, František FOLBER, Štěpán HRABOVSKÝ, Zdenek KORISTEK, Jan M HORACEK et. al.
Single Cycle of Blinatumomab Followed By High-Dose Chemotherapy in the Induction Therapy for Ph-Negative Acute Lymphoblastic Leukemia in Adults. Primary Endpoint Analysis of the Blina-Cell Trial
Autoři
SALEK, Cyril, František FOLBER (203 Česká republika, domácí), Štěpán HRABOVSKÝ (203 Česká republika, domácí), Zdenek KORISTEK, Jan M HORACEK, Eva FRONKOVA, Petr SOUKUP, Katerina BENKOVA, Petr CETKOVSKY, Jan TRKA a Michael DOUBEK
Background: Blinatumomab induces a high proportion of complete molecular responses in relapsed or refractory B-cell acute lymphoblastic leukemia (ALL) and ALL with persistent or recurrent measurable residual disease (MRD) after initial therapy. However, responses are generally short if they are not followed by allogeneic stem cell transplantation (HSCT). We infer that blinatumomab needs to be incorporated sequentially into the early phase of treatment to enhance rates of MRD negativity, lower the need of HSCT and improve survival.